IMV shares are trading higher after the company reported final topline results of DeCidE1 clinical trial in advanced recurrent ovarian cancer. The company said "Median Overall Survival was 19.9 months, and overall survival rate was 44.9% at 23.8 months."

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!